Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Potential Use of Dapaglifozin to Avoid Acute Kindey Injury (AKI) to Chronic Kidney Disease (CKD) Transition: DAKI-CKD Study

NCT05713851 is registered in ClinicalTrials.gov with Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran as lead sponsor.

NCT NCT05713851
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05713851 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Potential Use of Dapaglifozin to Avoid Acute Kindey Injury (AKI) to Chronic Kidney Disease (CKD) Transition: DAKI-CKD Study
Lead sponsor
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Phase
Phase 2/3
Overall status
Unknown status
Start date
January 1, 2023
Completion date
January 1, 2025
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aki - acute kidney injury, biomarkers, ckd, transition to ckd